Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 18/20 | 0.37 |
| ▸ | MTOR | P42345 | 8/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.36 |
| ▸ | ATR | Q13535 | 6/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27097804 | 0.97 | ATM (0.38) | METAP2ATMMTORPIK3CAATR | |
| SCHEMBL20128971 | 0.97 | ATM (0.38) | METAP2ATMMTORPIK3CAATR | |
| SCHEMBL20129067 | 0.87 | METAP2 (0.37) | METAP2ATMMTORPIK3CAATR | |
| SCHEMBL20128973 | 0.86 | METAP2 (0.37) | METAP2ATMMTORPIK3CAATR | |
| SCHEMBL27097805 | 0.86 | METAP2 (0.37) | METAP2ATMMTORPIK3CAATR | |
| SCHEMBL20128974 | 0.83 | ATM (0.40) | METAP2ATMNPC1POLBGAA | |
| SCHEMBL20129125 | 0.83 | ATM (0.39) | METAP2ATMMTORPIK3CAATR | |
| SCHEMBL20128932 | 0.82 | ATM (0.36) | ATMMTORPIK3CAATR | |
| SCHEMBL20120286 | 0.82 | ATM (0.34) | ATMMTORPIK3CAATR | |
| SCHEMBL29547272 | 0.82 | ATM (0.34) | ATMMTORPIK3CAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011913-A1 | TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2021-01-21 | — | — | WO | disclosed |
| WO-2018102067-A2 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | Arvinas, Inc. (US) | 2018-06-07 | — | — | WO | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. | 2018-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125821-A1 | TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE | CRBN, VHL, UBQLN2 | METAP2 954/4885ATM 959/4885MTOR 945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.